SBRT is an emerging treatment in oligometastatic esophagogastric cancer that can increase disease control and improve survival outcomes. It can have a role in different clinical scenarios , such as oligoprogressive or oligorecurrence disease in combination with systemic therapy. SBRT offers high local control rates, low toxicity profile and potential survival benefits in selected patients in particular for lung, liver and nodal metastases. Current evidence and future perspectives will be critically analyzed.
